Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.

Dr. Ben Levy discusses two trials that are trying to determine if immunotherapy can help lung cancer patients with earlier stage disease. Click here for information about the PACIFIC trial. The lung cancer vaccine trial will begin in early 2016.

Dr. Nathan Pennell discusses ALCHEMIST, an NCI-sponsored clinical trial looking at whether targeted post-op (adjuvant) therapy for patients with a driver mutation such as EGFR mutation or ALK rearrangement improves survival.

A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.

Please feel free to offer comments and raise questions in our Discussion Forums.

A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.

[powerpress]

As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which drugs while maintaining good quality of life.

[powerpress]

Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?

[powerpress]

Immunotherapy Forum Video #25: In Part 2 of 2 videos, Dr.

Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr.

Immunotherapy Forum Video #23: Dr. Jared Weiss highlights what doctors know about immunotherapy treatments for lung cancer.